CRB Inverbío

Aglaris is focused on developing automated cell culture bioreactors for the mass production of human stem cells. The company designs equipment that simplifies cell and tissue culture, enhancing the reliability and speed of the production process. By automating and controlling these processes, Aglaris aims to produce high-quality cells and tissues that can significantly advance regenerative medicine and cell therapies. Their technology is unique and protected by international patents, which helps minimize the need for human intervention and reduces contamination risks associated with cell handling. This innovation enables bio-entrepreneurs to generate new cells and improve their quality effectively.

Mecwins develops technology for nanomechanical sensing and uses its technology to produce sensitive immunoassays for oncology, cardiovascular disease, and infectious diseases. They improve the healthcare of those sections of the population who are particularly at risk.

Nuubo is a Spanish medical device company that develops wireless, wearable technologies to monitor physiological parameters. To do so, Nuubo has a platform known as nECG DYNAMIC PLATFORM, which makes it easier to perform and read an electrocardiogram remotely. Specifically, the system patented by Nuubo is made up of three elements: a biomedical garment that allows the electrocardiogram signal to be captured without interfering with the patient’s daily activity; a device that continuously records the information captured by the garment and which also allows the data to be sent wirelessly and in real time for processing; and analysis and visualization software that, using artificial intelligence algorithms, can interpret all of the information transmitted by the wireless device. The devices designed by Nuubo allow patients’ hearts to be monitored for longer periods of time and without feeling uncomfortable or intrusive. The company is headquartered in Madrid, Spain.

Amadix is focused on developing and commercializing innovative cancer diagnostic technologies that address unmet medical needs in oncology. The company's flagship product, Colofast, is a non-invasive screening signature for colorectal cancer and advanced adenoma diagnosis, aimed at reducing the high mortality rate associated with colon cancer. Amadix's approach emphasizes early detection, allowing for timely treatment while avoiding the complications of invasive procedures like tumor biopsies. The team comprises industry veterans with extensive expertise in oncology diagnostics, the pharmaceutical industry, and biotechnology, supported by independent board members who provide strategic guidance in commercialization and business development, particularly in Europe and the United States. Amadix's products undergo rigorous analytical validation and clinical studies before being introduced to the global market.

Chosen as one of Spain’s top 5 biotech investment opportunities, TCD is focused on creating the future of Oncology by developing innovative therapies that address unmet medical needs. Established in 2005 and with one product, TCD-717, already in clinical trials the Company is positioning itself as Spain’s Partner of Choice for Oncology drug discovery and development opportunities. TCD’s strong management team, its strategy of building its pipeline through in-licensing and partnerships and by leveraging resources through collaborations and outsourcing via premier Contract Research Organizations, allows TCD to be in the forefront of Oncology drug development while significantly lowering risks and costs.

Chosen as one of Spain’s top 5 biotech investment opportunities, TCD is focused on creating the future of Oncology by developing innovative therapies that address unmet medical needs. Established in 2005 and with one product, TCD-717, already in clinical trials the Company is positioning itself as Spain’s Partner of Choice for Oncology drug discovery and development opportunities. TCD’s strong management team, its strategy of building its pipeline through in-licensing and partnerships and by leveraging resources through collaborations and outsourcing via premier Contract Research Organizations, allows TCD to be in the forefront of Oncology drug development while significantly lowering risks and costs.